



Hostettler, I. C. et al. (2019) C9orf72 and intracerebral haemorrhage. *Neurobiology of Aging*, 84, 237.e1-237.e3.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/190686/>


Deposited on: 23 July 2019

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

Accepted Manuscript

C9orf72 and intracerebral haemorrhage

Isabel C. Hostettler, MD, Manuel Bernal-Quiros, PhD, Andrew Wong, PhD, Nikhil Sharma, FRCP PhD, Duncan Wilson, PhD, David Seiffge, MD, Clare Shakeshaft, Msc, Hans R. Jäger, MD, Hannah Cohen, PhD, Tarek Yousry, MD, Rustam Al-Shahi Salman, PhD, Gregory Y.H. Lip, FRCP, Martin M. Brown, FRCP, Keith W. Muir, MD FRCP, David J. Werring, FRCP PhD, Henry Houlden, PhD, on behalf of , the CROMIS-2 collaborators



PII: S0197-4580(19)30209-X

DOI: <https://doi.org/10.1016/j.neurobiolaging.2019.07.007>

Reference: NBA 10616

To appear in: *Neurobiology of Aging*

Received Date: 3 April 2019

Revised Date: 30 May 2019

Accepted Date: 10 July 2019

Please cite this article as: Hostettler, I.C, Bernal-Quiros, M., Wong, A., Sharma, N., Wilson, D., Seiffge, D., Shakeshaft, C., Jäger, H.R, Cohen, H., Yousry, T., Al-Shahi Salman, R., Lip, G.Y.H, Brown, M.M, Muir, K.W, Werring, D.J, Houlden, H., on behalf of the CROMIS-2 collaborators, *C9orf72* and intracerebral haemorrhage, *Neurobiology of Aging* (2019), doi: <https://doi.org/10.1016/j.neurobiolaging.2019.07.007>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

C9orf72 and intracerebral haemorrhage

Isabel C Hostettler MD^{1, 2}, Manuel Bernal-Quiros PhD², Andrew Wong PhD³, Nikhil Sharma FRCP PhD^{4, 5}, Duncan Wilson PhD¹, David Seiffge MD^{1, 6, 7}, Clare Shakeshaft MSc¹, Hans R Jäger MD⁸, Hannah Cohen PhD⁹, Tarek Yousry MD⁸, Rustam Al-Shahi Salman PhD¹⁰, Gregory Y H Lip FRCP^{11, 12}, Martin M Brown FRCP¹, Keith W Muir MD FRCP¹³, David J Werring FRCP PhD¹, Henry Houlden PhD² on behalf of the CROMIS-2 collaborators

¹Stroke Research Centre, University College London, Institute of Neurology, London, UK

²Neurogenetics Laboratory, The National Hospital of Neurology and Neurosurgery, London, UK

³MRC Unit for Lifelong Health and Ageing at UCL, London, UK

⁴Department of Neurology, The National Hospital of Neurology and Neurosurgery, London, UK

⁵Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology

⁶Stroke Centre and Neurology, University Hospital and University Basel, Switzerland

⁷Department of Neurology and Stroke Center, Inselspital, University Hospital Bern, Switzerland

⁸Neuroradiological Academic Unit, Department of Brain Repair & Rehabilitation, University

⁹Haemostasis Research Unit, Department of Haematology, University College London, 51 Chenies Mews, London, UK

¹⁰Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, UK

¹¹Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

¹²Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

¹³Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK

Corresponding author: Professor Henry Houlden FRCP PhD, Head of the Laboratory of Neurogenetics, The National Hospital of Neurology and Neurosurgery and UCL Institute of Neurology, University College London, Queen Square, WC1N 3BG London, United Kingdom, Phone: +44 20 3448 3141, Email: h.houlden@ucl.ac.uk

Keywords

Intracerebral haemorrhage, C9orf72, genetics, dementia, white matter changes, imaging markers

Declaration of interest: None.

Funding: HH and ICH received funding from the Alzheimer Research UK and Dunhill Medical Trust Foundation. DJW and DW received funding from the Stroke Foundation/British Heart Foundation. This work was undertaken at UCLH/UCL which receives a proportion of funding from the Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme.

These funding bodies had not direct involvement in this study.

Abstract

The *C9orf72* GGGGCC repeat expansion has been associated with several diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD). It has also been associated with increased white matter changes in FTD as well as risk of cognitive impairment in ALS. Dementia is common both before and after intracerebral haemorrhage (ICH). Since the mechanisms of cognitive impairment in patients with ICH are uncertain, we investigated whether *C9orf72* could influence dementia risk in this patient group. Therefore, we genotyped 1010 clinically characterised ICH cases and 2147 population controls in comparison with prior data of dementia and ALS cases. We did not find any association between *C9orf72* repeat expansion or repeat size with ICH compared to controls or with dementia when assessing ICH patients only. The frequency of *C9orf72* expansions in our series of individuals born in 1946 (2/2147) and other UK controls was age-dependent decreasing with increasing age, highlighting the high age-dependant penetrance of this expansion.

Introduction

The chromosome 9 open reading frame 72 (*C9orf72*) GGGGCC repeat expansion has been associated with several diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)(DeJesus-Hernandez et al., 2011; Renton et al., 2011). The number of repeats to discriminate between normal repeat and pathogenic expansion is unknown although the cut-off has been suggested at 30(Van Mossevelde et al., 2017). In patients with a pathogenic repeat expansion, the number of hexanucleotide copies can be in the thousands(DeJesus-Hernandez et al., 2011; Renton et al., 2011). *C9orf72* repeat expansions have previously been associated with white matter hyperintensities in FTD as well as cognitive impairment in ALS patients(Chio et al., 2016; Mahoney et al., 2015). Brain tissue of FTD patients have demonstrated amyloid beta plaques in some cases (2/51)(Simon-Sanchez et al., 2012). *C9orf72* repeat expansion may therefore influence pre-ICH dementia or an increased rate of dementia after the ICH event through similar mechanisms by acting on cerebrovascular factors such as small vessel diseases and cerebral amyloid angiopathy(Cordonnier et al., 2010; Moulin et al., 2016; Pendlebury and Rothwell, 2009; Xiong et al., 2016). We hypothesized that increasing numbers of GGGGCC repeats in absence of a pathogenic repeat expansion may be associated with or influence

pre-ICH dementia in ICH patients through a mechanism that influences small vessel disease (SVD) and cerebral amyloid angiopathy (CAA). To address this hypothesis, we genotyped 1010 clinically characterised ICH cases and 2147 controls and compared them with prior data of dementia and ALS cases.

Methods: Study cohort: The CROMIS-2 study was approved by the National Research Ethics Service (reference: 10/H0716/64). We included patients with available DNA who had been recruited to the CROMIS-2 (NCT02513316) ICH study(Charidimou et al., 2015). Population controls were from the Medical Research Council National Survey of Health and Development (NSHD), a socially stratified cohort of 5362 singleton births that occurred during 1 week in March 1946 in England, Scotland, and Wales(Kuh et al., 2016; Rousseau et al., 2006).

Genotyping: *C9orf72* screening was performed as previously described using sizing and repeat primed polymerase chain reaction (PCR)(DeJesus-Hernandez et al., 2011; Renton et al., 2011). In cases of suggested expansion, we performed Southern blot(DeJesus-Hernandez et al., 2011). We evaluated the number of repeats as continuous (dominant and additive) and binary variable (dichotomized into <20 and ≥ 20 repeats)(Rutherford et al., 2012; Van Mossevelde et al., 2017). To evaluate for dominant effect we used the number of repeats of the longer of the 2 normal alleles and for additive effect the summed repeat number of both alleles(Rutherford et al., 2012).

Outcome measures and procedures: Outcome variables in patients with ICH were history of dementia, SVD burden and CAA. We analysed SVD by assessing the overall burden of SVD on CT and possible and probable CAA using the modified Boston criteria(Arba et al., 2017; Linn et al., 2010). **Statistics:** Continuous variables are presented as means and SD if normally distributed, median and IQR if not normally distributed. Categorical variables are presented as number and percentage. In a second step we adjusted the regression model for age and sex. For possible and probable CAA, we adjusted for sex only. We performed all statistical analysis in STATA 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp).

Results

We analysed *C9orf72* in 3157 individuals: 1010 cases and 2147 controls (Supplementary Figure 1). The frequency of ICH patients heterozygous for *C9orf72* alleles was higher compared to controls (Supplementary Table 1 and Figure 2). See Supplementary Table 2 for an overview of allele counts. When considering allele count, we did not observe a significant difference between cases and controls (OR 1.03, 95%CI 0.99-1.07, $p=0.17$ for allele 1 and OR 0.99, 95%CI 0.97-1.02, $p=0.53$ for allele 2). However, when considering GGGGCC repeats as a binary variable (dichotomized into <20 or ≥ 20 repeats), controls more frequently had ≥ 20 repeats ($p=0.01$, supplementary Table 1). In fact, only 4 ICH patients had a repeat ≥ 20 (0.4%) compared to 34 controls (1.6%), none of these 4 ICH patients had a history of dementia. Two individuals had a pathogenic expansion (with >80 repeats), both of whom were from our control cohort (0.09% of NSHD population controls, supplementary Table 3 and Figure 3). No pathogenic expansion was found in the ICH cohort. In the ICH cohort a history of pre-ICH dementia was associated with age but not with repeats (supplementary Table 4) measured by dominant and additive repeat variable and homozygosity. We did not observe association between the dominant repeat variant and SVD burden (OR 0.99 per point increase, 95%CI 0.95-1.02, $p=0.42$) nor possible or probable CAA. None of the patients with ≥ 20 repeats had cognitive deficits, history of dementia or imaging markers.

Discussion

This is the first study to evaluate the influence of *C9orf72* alleles in an ICH cohort where we do not report pathogenic *C9orf72* repeat expansions. Controls had a higher frequency of higher repeats compared to ICH patients. We could not demonstrate an effect of number of repeats on history of dementia, SVD burden, nor CAA. We observed differences between ICH patients and controls in homozygous frequency, ICH patients more frequently heterozygous. Two controls had a pathogenic expansion (0.09%). Our findings suggest the expansion in population controls is lower than previously suggested. The absence of *C9orf72* repeat expansions in the ICH cohort is likely expected due to individuals with pathogenic expansions most likely having died by the time an individual suffers from an ICH (age of ALS onset ranges around 58 year of age for carrier of the *C9orf72* repeat expansion)(Chio et al., 2015; Murphy et al., 2017; Westeneng et al., 2018; Wijesekera and Leigh,

2009). The *C9orf72* expansion cut-off has been suggested at 30. Although cases and controls were different with regards to homozygous frequency and number of repeats, the percentage of individuals with ≥ 20 repeats was lower in both cohorts: 0.4% in ICH patients and 1.6% in population controls compared to previous results. The control data also highlights the lower frequency of *C9orf72* expansions in our NSHD controls (Kuh et al., 2016; Rousseau et al., 2006). Blood samples for the NSHD controls were taken when they were 53.5 years of age, therefore early death due to pathogenic expansion is unlikely causing the lower percentage of expansions (Supplemental Table 3 and Figure 3). ICH individuals with ≥ 20 repeats did not have an increased rate of history of pre-ICH dementia. In conclusion, *C9orf72* repeat are not associated with history of pre-ICH dementia, SVD markers or CAA in the ICH population. The prevalence of *C9orf72* GGGGCC repeat expansion in the normal population is lower than previously reported (Rutherford et al., 2012).

REFERENCES

- Arba, F., Mair, G., Carpenter, T., Sakka, E., Sandercock, P.A.G., Lindley, R.I., Inzitari, D., Wardlaw, J.M., Collaborators, I.S.T.T., 2017. Cerebral White Matter Hypoperfusion Increases with Small-Vessel Disease Burden. Data From the Third International Stroke Trial. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 26(7), 1506-1513.
- Charidimou, A., Wilson, D., Shakeshaft, C., Ambler, G., White, M., Cohen, H., Yousry, T., Al-Shahi Salman, R., Lip, G., Houlden, H., Jager, H.R., Brown, M.M., Werring, D.J., 2015. The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. *International journal of stroke : official journal of the International Stroke Society* 10 Suppl A100, 155-161.
- Chio, A., Brunetti, M., Barberis, M., Iazzolino, B., Montuschi, A., Ilardi, A., Cammarosano, S., Canosa, A., Moglia, C., Calvo, A., 2016. The Role of APOE in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. *JAMA neurology* 73(4), 425-430.
- Chio, A., Mora, G., Sabatelli, M., Caponnetto, C., Lunetta, C., Traynor, B.J., Johnson, J.O., Nalls, M.A., Calvo, A., Moglia, C., Borghero, G., Monsurro, M.R., La Bella, V., Volanti, P., Simone, I., Salvi, F., Logullo, F.O., Nilo, R., Giannini, F., Mandrioli, J., Tanel, R., Murru, M.R., Mandich, P., Zollino, M., Conforti, F.L., Penco, S., consortium, I., consortium, S., Brunetti, M., Barberis, M., Restagno, G., 2015. HFE p.H63D polymorphism does not influence ALS phenotype and survival. *Neurobiology of aging* 36(10), 2906 e2907-2911.
- Cordonnier, C., Leys, D., Dumont, F., Deramecourt, V., Bordet, R., Pasquier, F., Henon, H., 2010. What are the causes of pre-existing dementia in patients with intracerebral haemorrhages? *Brain : a journal of neurology* 133(11), 3281-3289.
- DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G.Y., Karydas, A., Seeley, W.W., Josephs, K.A., Coppola, G., Geschwind, D.H., Wszolek, Z.K., Feldman, H., Knopman, D.S., Petersen, R.C., Miller, B.L., Dickson, D.W., Boylan, K.B., Graff-

- 1 Radford, N.R., Rademakers, R., 2011. Expanded GGGGCC hexanucleotide repeat in noncoding
2 region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72(2), 245-256.
- 3 Kuh, D., Wong, A., Shah, I., Moore, A., Popham, M., Curran, P., Davis, D., Sharma, N., Richards,
4 M., Stafford, M., Hardy, R., Cooper, R., 2016. The MRC National Survey of Health and
5 Development reaches age 70: maintaining participation at older ages in a birth cohort study. *Eur J*
6 *Epidemiol* 31(11), 1135-1147.
- 7 Linn, J., Halpin, A., Demaerel, P., Ruhland, J., Giese, A.D., Dichgans, M., van Buchem, M.A.,
8 Bruckmann, H., Greenberg, S.M., 2010. Prevalence of superficial siderosis in patients with cerebral
9 amyloid angiopathy. *Neurology* 74(17), 1346-1350.
- 10 Mahoney, C.J., Simpson, I.J., Nicholas, J.M., Fletcher, P.D., Downey, L.E., Golden, H.L., Clark,
11 C.N., Schmitz, N., Rohrer, J.D., Schott, J.M., Zhang, H., Ourselin, S., Warren, J.D., Fox, N.C.,
12 2015. Longitudinal diffusion tensor imaging in frontotemporal dementia. *Annals of neurology*
13 77(1), 33-46.
- 14 Moulin, S., Labreuche, J., Bombois, S., Rossi, C., Boulouis, G., Henon, H., Duhamel, A., Leys, D.,
15 Cordonnier, C., 2016. Dementia risk after spontaneous intracerebral haemorrhage: a prospective
16 cohort study. *The Lancet. Neurology* 15(8), 820-829.
- 17 Murphy, N.A., Arthur, K.C., Tienari, P.J., Houlden, H., Chio, A., Traynor, B.J., 2017. Age-related
18 penetrance of the C9orf72 repeat expansion. *Sci Rep* 7(1), 2116.
- 19 Pendlebury, S.T., Rothwell, P.M., 2009. Prevalence, incidence, and factors associated with pre-
20 stroke and post-stroke dementia: a systematic review and meta-analysis. *The Lancet. Neurology*
21 8(11), 1006-1018.
- 22 Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R., Schymick,
23 J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y.,
24 Remes, A.M., Kaganovich, A., Scholz, S.W., Duckworth, J., Ding, J., Harmer, D.W., Hernandez,
25 D.G., Johnson, J.O., Mok, K., Ryten, M., Trabzuni, D., Guerreiro, R.J., Orrell, R.W., Neal, J.,
26 Murray, A., Pearson, J., Jansen, I.E., Sondervan, D., Seelaar, H., Blake, D., Young, K., Halliwell,
27 N., Callister, J.B., Toulson, G., Richardson, A., Gerhard, A., Snowden, J., Mann, D., Neary, D.,
28 Nalls, M.A., Peuralinna, T., Jansson, L., Isoviita, V.M., Kaivorinne, A.L., Holtta-Vuori, M., Ikonen,
29 E., Sulkava, R., Benatar, M., Wu, J., Chio, A., Restagno, G., Borghero, G., Sabatelli, M.,
30 Consortium, I., Heckerman, D., Rogaeva, E., Zinman, L., Rothstein, J.D., Sendtner, M., Drepper,
31 C., Eichler, E.E., Alkan, C., Abdullaev, Z., Pack, S.D., Dutra, A., Pak, E., Hardy, J., Singleton, A.,
32 Williams, N.M., Heutink, P., Pickering-Brown, S., Morris, H.R., Tienari, P.J., Traynor, B.J., 2011.
33 A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-
34 FTD. *Neuron* 72(2), 257-268.
- 35 Rousseau, K., Vinall, L.E., Butterworth, S.L., Hardy, R.J., Holloway, J., Wadsworth, M.E.,
36 Swallow, D.M., 2006. MUC7 haplotype analysis: results from a longitudinal birth cohort support
37 protective effect of the MUC7*5 allele on respiratory function. *Ann Hum Genet* 70(Pt 4), 417-427.
- 38 Rutherford, N.J., Heckman, M.G., DeJesus-Hernandez, M., Baker, M.C., Soto-Ortolaza, A.I.,
39 Rayaprolu, S., Stewart, H., Finger, E., Volkening, K., Seeley, W.W., Hatanpaa, K.J., Lomen-
40 Hoerth, C., Kertesz, A., Bigio, E.H., Lippa, C., Knopman, D.S., Kretzschmar, H.A., Neumann, M.,
41 Caselli, R.J., White, C.L., 3rd, Mackenzie, I.R., Petersen, R.C., Strong, M.J., Miller, B.L., Boeve,
42 B.F., Uitti, R.J., Boylan, K.B., Wszolek, Z.K., Graff-Radford, N.R., Dickson, D.W., Ross, O.A.,
43 Rademakers, R., 2012. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence
44 disease phenotype. *Neurobiology of aging* 33(12), 2950 e2955-2957.
- 45 Simon-Sanchez, J., Dopper, E.G., Cohn-Hokke, P.E., Hukema, R.K., Nicolaou, N., Seelaar, H., de
46 Graaf, J.R., de Koning, I., van Schoor, N.M., Deeg, D.J., Smits, M., Raaphorst, J., van den Berg,
47 L.H., Schelhaas, H.J., De Die-Smulders, C.E., Majoor-Krakauer, D., Rozemuller, A.J., Willemsen,
48 R., Pijnenburg, Y.A., Heutink, P., van Swieten, J.C., 2012. The clinical and pathological phenotype
49 of C9ORF72 hexanucleotide repeat expansions. *Brain : a journal of neurology* 135(Pt 3), 723-735.
- 50 Van Mossevelde, S., van der Zee, J., Cruts, M., Van Broeckhoven, C., 2017. Relationship between
51 C9orf72 repeat size and clinical phenotype. *Curr Opin Genet Dev* 44, 117-124.

- 1 Westeneng, H.J., Debray, T.P.A., Visser, A.E., van Eijk, R.P.A., Rooney, J.P.K., Calvo, A., Martin,
2 S., McDermott, C.J., Thompson, A.G., Pinto, S., Kobeleva, X., Rosenbohm, A., Stubendorff, B.,
3 Sommer, H., Middelkoop, B.M., Dekker, A.M., van Vugt, J., van Rheenen, W., Vajda, A., Heverin,
4 M., Kazoka, M., Hollinger, H., Gromicho, M., Korner, S., Ringer, T.M., Rodiger, A., Gunkel, A.,
5 Shaw, C.E., Bredenoord, A.L., van Es, M.A., Corcia, P., Couratier, P., Weber, M., Grosskreutz, J.,
6 Ludolph, A.C., Petri, S., de Carvalho, M., Van Damme, P., Talbot, K., Turner, M.R., Shaw, P.J.,
7 Al-Chalabi, A., Chio, A., Hardiman, O., Moons, K.G.M., Veldink, J.H., van den Berg, L.H., 2018.
8 Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a
9 personalised prediction model. *The Lancet. Neurology* 17(5), 423-433.
- 10 Wijesekera, L.C., Leigh, P.N., 2009. Amyotrophic lateral sclerosis. *Orphanet journal of rare*
11 *diseases* 4, 3.
- 12 Xiong, L., Reijmer, Y.D., Charidimou, A., Cordonnier, C., Viswanathan, A., 2016. Intracerebral
13 hemorrhage and cognitive impairment. *Biochimica et biophysica acta* 1862(5), 939-944.

14